Magnetic Control of Polymorphism in Pharmaceutical Compounds

Informazioni relative al progetto

MagnaPharm

ID dell’accordo di sovvenzione: 736899

DOI 10.3030/736899

Progetto concluso

Data della firma CE 13 Dicembre 2016

Data di avvio 1 Gennaio 2017

Data di completamento 30 Giugno 2021

Finanziato da

• EXCELLENT SCIENCE - Future and Emerging Technologies (FET)

Costo totale € 2 886 323,75

Contributo UE € 2 886 323,75

Coordinato da

UNIVERSITY OF BRISTOL
United Kingdom

Obiettivo

This H2020-FETOPEN-2016-2017 proposal initiates a major international effort to direct polymorphism in pharmaceutical compounds through crystallizing in high magnetic fields. The ability to direct polymorphism would have a transformative effect on almost all pharmaceutical compounds, and hence on society.

It is proposed that MagnaPharm will drive forward innovation in pharmaceuticals by exploiting our new discovery that the polymorph and properties of carbamazepine, indomethacin and coronene can be controlled through the application of magnetic fields. We will apply our method to a range of pharmaceutical compounds, as guided by our project partner AstraZeneca, one of the largest pharmaceutical companies in the world. We will initially target 12 of the most high-profile, high-worth generic drugs with the aim of controllably synthesizing the desired polymorph of each (the lowest-energy polymorph and/or most processable form with desired properties). We aim for this goal via an international multidisciplinary approach centred around our discovery, underpinned by the development of a profound theoretical understanding of the effects of magnetic fields on organic crystal growth, that will direct the synthetic effort, all drawing on results from cutting edge spectroscopic and crystallographic characterisations.

With the 12 representative generic drug molecules targeted in the initial stages of MagnaPharm responsible for €18 billion of sales per year worldwide, and the development of many new pharmaceuticals being hampered by solid form issues, control over the production of the most pharmaceutically desired crystal is a truly paradigm-shifting prospect.

Campo scientifico

• engineering and technology › materials engineering › crystals
• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs

Programma(i)

• H2020-EU.1.2. - EXCELLENT SCIENCE - Future and Emerging Technologies (FET) Main Programme
• H2020-EU.1.2.1. - FET Open

Argomento(i)

• FETOPEN-01-2016-2017 - FET-Open research and innovation actions

Invito a presentare proposte

H2020-FETOPEN-2016-2017

Vedi altri progetti per questo bando

Bando secondario

H2020-FETOPEN-1-2016-2017

Meccanismo di finanziamento

RIA - Research and Innovation action

Coordinatore

UNIVERSITY OF BRISTOL

• Contribution nette de l'UE: € 1 195 677,50
• Indirizzo: BEACON HOUSE QUEENS ROAD ; BS8 1QU Bristol ; Regno Unito
• Regione: South West (England) › Gloucestershire, Wiltshire and Bristol/Bath area › Bristol, City of
• Tipo di attività: Higher or Secondary Education Establishments
• Costo totale: € 1 195 677,50

Partecipanti (3)

UNIVERSITY COLLEGE LONDON

Regno Unito

• Contribution nette de l'UE: € 775 673,75
• Indirizzo: GOWER STREET ; WC1E 6BT London
• Regione: London › Inner London — West › Camden and City of London
• Tipo di attività: Higher or Secondary Education Establishments
• Costo totale: € 775 673,75

STICHTING RADBOUD UNIVERSITEIT

Paesi Bassi

• Contribution nette de l'UE: € 360 031,25
• Indirizzo: HOUTLAAN 4 ; 6525 XZ Nijmegen
• Regione: Oost-Nederland › Gelderland › Arnhem/Nijmegen
• Tipo di attività: Higher or Secondary Education Establishments
• Costo totale: € 360 031,25

UNIVERSITY OF LIMERICK

Irlanda

• Contribution nette de l'UE: € 554 941,25
• Indirizzo: NATIONAL TECHNOLOGICAL PARK, PLASSEY ; - Limerick
• Regione: Ireland › Northern and Western › Border
• Tipo di attività: Higher or Secondary Education Establishments
• Costo totale: € 554 941,25